Cargando…

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology

BACKGROUND: Unexpected differences in Ki-67 values among HER2 & ER/PgR defined subgroups were found. This study aims to detect possible subdivisions beyond the conventional breast cancer types. METHODS: One thousand one hundred eighty consecutive patients with invasive ductal breast carcinoma we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurbel, Sven, Dmitrović, Branko, Marjanović, Ksenija, Vrbanec, Damir, Juretić, Antonije
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372302/ https://www.ncbi.nlm.nih.gov/pubmed/28356061 http://dx.doi.org/10.1186/s12885-017-3212-x

Ejemplares similares

A model of immunohistochemical differences between invasive breast cancers and DCIS lesions tested on a consecutive case series of 1248 patients
por: Kurbel, Sven, et al.
Publicado: (2014)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer
por: Dobrescu, Andrei, et al.
Publicado: (2011)

IHC Color Histograms for Unsupervised Ki67 Proliferation Index Calculation
por: Geread, Rokshana S., et al.
Publicado: (2019)

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
por: Tagliaferri, Barbara, et al.
Publicado: (2020)

New Robust and Reproducible Stereological IHC Ki67 Breast Cancer Proliferative Assessment to Replace Traditional Biased Labeling Index
por: Bigras, Gilbert, et al.
Publicado: (2017)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer
por: Kriegmair, M.C., et al.
Publicado: (2018)

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
por: Wu, Natalie C., et al.
Publicado: (2018)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

S100A9 expressed in ER(−)PgR(−) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
por: Bergenfelz, Caroline, et al.
Publicado: (2015)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast
por: SUCIU, CRISTIAN, et al.
Publicado: (2014)

Ki67 and breast cancer mortality in women with invasive breast cancer
por: Probert, Jake, et al.
Publicado: (2023)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

URINARY BLADDER CANCER RECURRENCE AND EXPRESSION OF LYNCH AND HER MARKERS: SEARCHING FOR IMMUNOHISTOCHEMICAL PATTERNS AMONG 113 TUMORS FROM 33 PATIENTS
por: Matić, Mate, et al.
Publicado: (2022)

Ki-67 biomarker in breast cancer of Indian women
por: Patil, Amit V., et al.
Publicado: (2011)

Interobserver Variability of Ki-67 Measurement in Breast Cancer
por: Chung, Yul Ri, et al.
Publicado: (2016)

Ki-67, an elusive marker in the prognosis of breast cancer
por: Sood, Neelam
Publicado: (2019)

Association of Ki-67 With Clinicopathological Factors in Breast Cancer
por: ., Nishit, et al.
Publicado: (2021)

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype
por: Lazzeroni, M, et al.
Publicado: (2013)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

A novel model for Ki67 assessment in breast cancer
por: Romero, Quinci, et al.
Publicado: (2014)

Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
por: Davey, Matthew G., et al.
Publicado: (2021)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies
por: Zhou, Chen, et al.
Publicado: (2022)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group
por: Boyaci, Ceren, et al.
Publicado: (2021)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer
por: Mohammed, Z M A, et al.
Publicado: (2012)

Predicting of Ki-67 Expression Level Using Diffusion-Weighted and Synthetic Magnetic Resonance Imaging in Invasive Ductal Breast Cancer
por: Zhang, Liying, et al.
Publicado: (2023)

Breast cancer Ki-67 expression prediction by digital breast tomosynthesis radiomics features
por: Tagliafico, Alberto Stefano, et al.
Publicado: (2019)

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
por: Bouzubar, N., et al.
Publicado: (1989)

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.
por: Railo, M., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_on78dj5i6bc0riogdpp4jat6vh